CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 43,165,527	$ 41,004,601	$ 24,949,473
Cost of revenue	11,047,350	11,052,409	7,363,919
Gross profit	32,118,177	29,952,192	17,585,554
Operating expenses:
Research and development	16,380,930	8,810,561	12,091,797
Legal, financial and other consulting	2,731,515	3,048,242	2,462,151
Selling, general and administrative	35,750,477	28,463,723	22,005,670
Total operating expenses	54,862,922	40,322,526	36,559,618
Loss from operations	(22,744,745)	(10,370,334)	(18,974,064)
Other income (expense):
Interest (expense), net	28,007	(1,201,067)	(1,033,661)
Gain/(loss) on foreign currency transactions	(2,577,913)	2,607,139	(350,365)
Total other income (expense), net	(2,549,906)	1,406,072	(1,384,026)
Loss before benefit from income taxes	(25,294,651)	(8,964,262)	(20,358,090)
Benefit from income taxes	736,003	1,127,074	1,092,446
Net loss attributable to common shareholders	$ (24,558,648)	$ (7,837,188)	$ (19,265,644)
Basic net loss per common share	$ (0.57)	$ (0.20)	$ (0.60)
Diluted net loss per common share	$ (0.57)	$ (0.20)	$ (0.60)
Weighted average number of shares of common stock outstanding, basic	43,359,186	38,818,990	32,255,253
Weighted average number of shares of common stock outstanding, diluted	43,359,186	38,818,990	32,255,253
Comprehensive loss:
Net loss	$ (24,558,648)	$ (7,837,188)	$ (19,265,644)
Other comprehensive income (loss):
Currency translation adjustment	2,259,663	(2,260,056)	237,803
Comprehensive loss	(22,298,985)	(10,097,244)	(19,027,841)
Product
Revenue:
Total revenue	40,108,567	39,452,502	22,765,854
Cyto Sorb Sales
Revenue:
Total revenue	39,996,700	39,342,102	22,545,754
Other Sales
Revenue:
Total revenue	111,867	110,400	220,100
Grant
Revenue:
Total revenue	$ 3,056,960	$ 1,552,099	$ 2,183,619